Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The overarching aim of this trial is to evaluate naltrexone's efficacy in light of genetic
variation and brain response to alcohol cues utilizing a neuroimaging paradigm. This trial
has four specific aims. First, this trial will evaluate whether the presence of the OPRM1
Asp40 allele substitution is associated with improved treatment response to naltrexone in
treatment-seeking alcoholics. Second, it will evaluate whether there is a difference in the
naltrexone dampening of the alcohol cue-induced brain activation dependent on OPRM1 genotype.
Third, it will explore whether alcohol cue-induced brain activation dampening by naltrexone
might be a mediating factor in the treatment effects of naltrexone, the OPRM1 gene, or their
interaction that might be observed in the first aim. Finally, this trial will evaluate the
effect of medication compliance, or adverse effects, on the observed medication by genotype
treatment response. A secondary aim will measure medication compliance and side effects based
on OPRM1 genotype.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)